DE FAAKTO OUTBREAK INTELLIGENCE
SITUATION-EBOLA VIRUS VACCINE STUDY
FROM–Ministere de la Sante Republique Democratique du Congo
BACKGROUND-PRELIMINARY STUDY RESULTS EFFICACY OF THE VACCINE TO CONTROL THE EBOLA OUTBREAK-PUBLISHED BY NATIONAL INSTITUTE OF BIOMEDICAL RESEARCH & THE WORLD HEALTH ORGANIZATION
A study on the efficacy of the rVSV-ZEBOV-GP vaccine to control the Ebola outbreak has been published by the National Institute of Biomedical Research and the World Health organization
- The objective of the study was to better understand if the vaccine was effective and help prevent the number of cases when used as part of the belt vaccination strategy
- A more detailed analysis is being prepared and will be published in a scientific journal
- Researchers analyzed the data of those vaccinated between 1 st May 2018 and 25 March 2019
- According to the data collected, the efficiency of the rVSV-GP-ZEBOV vaccine is estimated at 97.5%
- Results confirm previous observations on the very high efficacy of the rVSV-ZEBOV-GP against Ebola vaccine to control the spread of the epidemic
- A sample of over 90,000 people vaccinated against Ebola, 71 developed the disease
- Of these 71 people, 15 people developed the disease more than 10 days after vaccination, of which 7 were health workers. In this first group, no one died of Ebola
- The other 56 people developed the first symptoms less than 10 days after being vaccinated, that is, before they could develop their immunity
- It is estimated that the vaccine takes 10 days to offer maximum immune protection
- In a second vaccination group, 9 people died
- This indicates that the vaccine has reduced the overall mortality rate among the vaccinated people who developed the disease (INRB & WHO, 2019)
EPIDEMIOLOGICAL SITUATION DEMOCRATIC REPUBLIC OF CONGO
13 April 2019-Ministere de la Sante Republique Democratique du Congo
- 1240 Ebola cases
- 1174 confirmed Ebola cases
- 66 probable Ebola cases
- 792 Ebola deaths
About Ebola
- Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever, is a severe, often fatal illness in humans
- The virus is transmitted to people from wild animals and spreads in the human population through human-to-human transmission
- The average EVD case fatality rate is around 50%. Case fatality rates have varied from 25% to 90% in past outbreaks
- The first EVD outbreaks occurred in remote villages in Central Africa, near tropical rainforests. The 2014–2016 outbreak in West Africa involved major urban areas as well as rural ones
- Community engagement is key to successfully controlling outbreaks. Good outbreak control relies on applying a package of interventions, namely case management, infection prevention and control practices, surveillance and contact tracing, a good laboratory service, safe and dignified burials and social mobilization
- Early supportive care with re-hydration, symptomatic treatment improves survival. There is as yet no licensed treatment proven to neutralize the virus but a range of blood, immunological and drug therapies are under development (WHO, 2019)
Ministere de la Sante Republique Democratique du Congo https://us13.campaign-archive.com/?u=89e5755d2cca4840b1af93176&id=cfa55c58ea
WHO https://www.who.int/news-room/fact-sheets/detail/ebola-virus-disease
